Product Data Sheet

Elacridar



Cat. No.:	A3384
CAS No.:	143664-11-3
Formula:	C34H33N3O5
M.Wt:	563.64
Synonyms:	GF120918;GW0918;GG918;GF-120918;GF 120918
Target:	Others
Pathway:	Others
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

≥56.4 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1mg	5mg	10mg
1 mM	1.7742 mL	8.8709 mL	17.7418 mL
5 mM	0.3548 mL	1.7742 mL	3.5484 mL
10 mM	0.1774 mL	0.8871 mL	1.7742 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	BCRP inhibitor
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	Human renal carcinoma cell lines 786-O and human breast cancer cell line MCF-7
Preparation method:	The solubility of this compound in DMSO is > 56.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored

		below -20°C for several months.
	Reacting conditions:	5 μM, 24 h
	Applications:	Elacridar is a P-glycoprotein inhibitor that also block ABC Sub-family B Member 2 (ABCG2). Elacridar significantly enhanced sunitinib-induced cytotoxicity in 786-O cells. Confirmed by P-glycoprotein function assay, P-glycoprotein activity was inhibited by elacridar.
In Vivo	**Animal experiment**	
	Animal models:	10-14-week wild-type, Abcb1a/1b-/-, 32Abcg2-/-27 and Abcb1a/1b/Abcg2-/- mice, all of a >99% FVB genetic background
	Dosage form:	Oral administration, 100 mg/kg
	Applications:	Elacridar significantly increased sunitinib brain accumulation in wild-type mice (12-fold), to levels equal to those in Abcb1a/1b/Abcg2-/- mice. The sunitinib brain concentrations were not significantly affected by elacridar treatment in Abcb1a/1b/Abcg2-/- mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Sato H, Siddig S, Uzu M, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells[J]. European journal of pharmacology, 2015, 746: 258-266.

[2]. Tang S C, Lagas J S, Lankheet N A G, et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration[J]. International journal of cancer, 2012, 130(1): 223-233.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt

of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com